Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Intervascular Post-Market Clinical Follow-Up (PMCF) Registry

NCT07322913 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this registry is to evaluate the long-term safety and performance of Intervascular Vascular Grafts and Patches (Intergard Standard, Hemashield, Intergard Silver, Intergard Synergy) for bypass, repair or replacement of aortic, peripheral, or carotid arteries. This registry is intended to further define the expected product lifetime of the devices and to collect data related to usefulness of the antimicrobial coatings.

Interventions

  • DEVICE Intergard Standard - Collagen Coated Vascular Grafts and Patches
  • DEVICE Hemashield - Collagen Coated Vascular Grafts and Patches
  • DEVICE Intergard Silver - Antimicrobial Collagen Coated Vascular Grafts and Patches
  • DEVICE Intergard Synergy - Antimicrobial Collagen Coated Vascular Grafts

Study Locations (3)

Other

  • CHU Dijon Bourgogne — Dijon
  • Hospital Universitario de Navarra — Pamplona

Pennsylvania

  • Allegheny General Hospital — Pittsburgh

Trial Details

FieldValue
Enrollment Target 1,200 participants
Start Date 2025-12-19
Est. Completion 2026-12

Sponsor

Intervascular

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07322913

The ClinicalTrials.gov registry entry for NCT07322913 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intervascular, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Aortic Diseases appearing as the primary indexed condition, and to 4 interventions — of which Intergard Standard - Collagen Coated Vascular Grafts and Patches is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07322913 reports 3 study locations spanning 2 distinct geographic areas — top geographies include Other, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07322913 about?

NCT07322913 is a clinical study titled "Intervascular Post-Market Clinical Follow-Up (PMCF) Registry". The purpose of this registry is to evaluate the long-term safety and performance of Intervascular Vascular Grafts and Patches (Intergard Standard, Hemashield, Intergard Silver, Intergard Synergy) for bypass, repair or replacement of aortic, peripheral, or carotid arteries. This registry is intended ...

What is the current status of trial NCT07322913?

This trial is currently recruiting. The enrollment target is 1,200 participants. The study started on 2025-12-19. Estimated completion is 2026-12.

What conditions does trial NCT07322913 study?

This clinical trial studies the following conditions: Aortic Diseases, Carotid Artery Diseases, Peripheral Arterial Diseases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07322913?

The interventions under investigation include: Intergard Standard - Collagen Coated Vascular Grafts and Patches (DEVICE), Hemashield - Collagen Coated Vascular Grafts and Patches (DEVICE), Intergard Silver - Antimicrobial Collagen Coated Vascular Grafts and Patches (DEVICE), Intergard Synergy - Antimicrobial Collagen Coated Vascular Grafts (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07322913?

This trial is sponsored by Intervascular, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07322913 being conducted?

This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial